What Is the Value of Innovative Pharmaceutical Therapies in Oncology and Hematology? A Willingness-to-Pay Study in Bulgaria

Искров, Георги; Greenberg, Dan; Yakimov, Ivan A.; Cholakova, Hristina; Стефанов, Румен

doi:10.1016/j.vhri.2019.03.005

Cited by 7 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Table 5 displays common patterns in societal monetary values for health gains by methodology for both the direct and the indirect approaches. We found that the monetary value of a QALY varied extensively as determined inter alia by the study's perspective, 22,57 type of respondents, 48,49,61,66,67 context, 22,47,61 hypothetical scenarios, 24,32,46,48,54,58,60,64,68 type and difference in QALY gain, [21][22][23][24]33,34,37,44,51,55 payment vehicle, 21,43,52 utility and cost elicitation methods, 14,31,32,41,54,63,70 and analytic approach. 39,42,45,53,59 Quality Assessment…”

Section: Estimates Of Monetary Value For Health Gainmentioning

confidence: 99%

A Systematic Review of Demand-Side Methods of Estimating the Societal Monetary Value of Health Gain

et al. 2021

View full text Add to dashboard Cite

Objectives: Although many reviews of the literature on cost-effectiveness thresholds (CETs) exist, the availability of new studies and the absence of a fully comprehensive analysis warrant a new review. This study systematically reviews demand-side methods for estimating the societal monetary value of health gain.Methods: Several electronic databases were searched from inception to October 2019. To be included, a study had to be an original article in any language, with a clearly described method for estimating the societal monetary values of health gain and with all estimated values reported. Estimates were converted to US dollars ($), using purchasing power parity (PPP) exchange rates and the gross domestic product (GDP) per capita (2019).Results: We included 53 studies; 45 used direct approach and 8 used indirect approach. Median estimates from the direct approach were PPP$ 24 942 (range 554-1 301 912) per quality-adjusted life-year (QALY), which were typically 0.53 (range 0.02-24.08) GDP per capita. Median estimates using the indirect approach were PPP$ 310 051 (range 36 402-7 574 870) per QALY, which accounted for 7.87 (range 0.68-116.95) GDP per capita.Conclusions: Our review found that the societal values of health gain or CETs were less than GDP per capita. The great variety in methods and estimates suggests that a more standardized and internationally agreed methodology for estimating CET is warranted. Multiple CETs may have a role when QALYs are not equally valued from a societal perspective (eg, QALYs accruing to people near death compared with equivalent QALYs to others).

show abstract

Section: Estimates Of Monetary Value For Health Gainmentioning

confidence: 99%

A Systematic Review of Demand-Side Methods of Estimating the Societal Monetary Value of Health Gain

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Regarding the type of hypothetical scenario, most studies were not specific to any disease/illness (62.5%), and the arguments concern its easy implementation. For those studies that applied a specific disease in the hypothetical scenario, the threshold value was positively associated with disease severity; for example, a severe cancer scenario would lead to higher threshold values [ 6 , 51 , 93 ] than mild ones, such as facial reanimation [ 34 , 36 ]. Further investment is needed to determine whether multiple threshold values should be applied within a country, i.e., according to the disease severity or specific population, such as children.…”

Section: Discussionmentioning

confidence: 99%

“…Threshold values have been established in Europe [ 3 , 6 – 26 ], the US [ 27 – 36 ], and a few Asian countries, such as Iran [ 37 – 41 ], Thailand [ 42 – 44 ], Japan [ 45 – 47 ], China [ 48 , 49 ], and Malaysia [ 50 ], but only two studies were conducted in LMICs, including Thailand in 2008 [ 42 ] and Vietnam in 2018 [ 51 ]. Although World Health Organization (WHO) had no longer recommended a threshold value between 1–3 times the gross domestic product (GDP) per capita per DALY averted [ 52 – 54 ], in countries that lack their own threshold values, this value has still often applied, especially in LMICs [ 55 ].…”

Section: Introductionmentioning

confidence: 99%

“…In general, the median WTP per QALY of countries varied significantly from i$2,643.6 to i$145,833.8, with the lowest in Greece and the largest value in Bulgaria. The study in Bulgaria interviewed doctors, with metastatic cancer as a hypothetical scenario; hence, this resulted in a high WTP/QALY value and high ratio of WTP per QALY per GDP per capita[6]. However, the median WTP per QALY for all countries was i$16,647.6, while the median WTP per QALY per GDP per capita of all studies was 0.534.To reference the WTP per QALY values per GDP per capita of each country, a boxplot chart is shown (Fig3).…”

mentioning

confidence: 99%

See 1 more Smart Citation

A systematic review on the direct approach to elicit the demand-side cost-effectiveness threshold: Implications for low- and middle-income countries

Nu Vu,

Hoang,

Lindholm

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Several literature review studies have been conducted on cost-effectiveness threshold values. However, only a few are systematic literature reviews, and most did not investigate the different methods, especially in-depth reviews of directly eliciting WTP per QALY. Our study aimed to 1) describe the different direct approach methods to elicit WTP/QALY; 2) investigate factors that contribute the most to the level of WTP/QALY value; and 3) investigate the relation between the value of WTP/QALY and GDP per capita and give some recommendations on feasible methods for eliciting WTP/QALY in low- and middle-income countries (LMICs). A systematic review concerning select studies estimating WTP/QALY from a direct approach was carried out in seven databases, with a cut off date of 03/2022. The conversion of monetary values into 2021 international dollars (i$) was performed via CPI and PPP indexes. The influential factors were evaluated with Bayesian model averaging. Criteria for recommendation for feasible methods in LMICs are made based on empirical evidence from the systematic review and given the resource limitation in LMICs. A total of 12,196 records were identified; 64 articles were included for full-text review. The WTP/QALY method and values varied widely across countries with a median WTP/QALY value of i$16,647.6 and WTP/QALY per GDP per capita of 0.53. A total of 11 factors were most influential, in which the discrete-choice experiment method had a posterior probability of 100%. Methods for deriving WTP/QALY vary largely across studies. Eleven influential factors contribute most to the level of values of WTP/QALY, in which the discrete-choice experiment method was the greatest affected. We also found that in most countries, values for WTP/QALY were below 1 x GDP per capita. Some important principles are addressed related to what LMICs may be concerned with when conducting studies to estimate WTP/QALY.

show abstract

“…Друга централна тема е качеството на живот и подходите за отчитането му при икономически анализ [2]. При хроничните незаразни болести това се явява едва ли не основен показател за ефикасност и терапевтична ефективност, но отсъствието на синергия между него и показателите за фармакоикономическа оценка често затруднява регулаторите при вземане на решение [5].…”

unclassified

Нови Методи За Оценка На Здравните Технологии В Отговор На Предизвикателствата На Иновативните Терапии

Искров¹,

Стефанов²

2020

Редки болести и лекарства сираци

View full text Add to dashboard Cite

От самото си създаване преди 20 г. National Institute for Health and Care Excellence (NICE) се утвърди като своеобразен ориентир по отношение на иновативните здравни технологии и достъпа до тях. Показателно за огромния интерес към опита на тази организация е съществуването на специално обособен отдел за международно сътрудничество, имащ за цел извършване на консултантска и експертна дейност. Регулаторни агенции от цял свят стриктно следят решенията на NICE. Едно положително или отрицателно становище може да предопредели достъпа на пациенти и клиничната практика далеч отвъд Великобритания. Бидейки едва ли не в самия център на иновации в медицината и здравеопазването, през 2019 г. NICE обяви, че ще извърши преглед и актуализиране на методологията си за оценка на здравните технологии.

show abstract

What Is the Value of Innovative Pharmaceutical Therapies in Oncology and Hematology? A Willingness-to-Pay Study in Bulgaria

Cited by 7 publications

References 32 publications

A Systematic Review of Demand-Side Methods of Estimating the Societal Monetary Value of Health Gain

A Systematic Review of Demand-Side Methods of Estimating the Societal Monetary Value of Health Gain

A systematic review on the direct approach to elicit the demand-side cost-effectiveness threshold: Implications for low- and middle-income countries

Нови Методи За Оценка На Здравните Технологии В Отговор На Предизвикателствата На Иновативните Терапии

Contact Info

Product

Resources

About